B-CELL LYMPHOMA REFRACTORY
Clinical trials for B-CELL LYMPHOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new B-CELL LYMPHOMA REFRACTORY trials appear
Sign up with your email to follow new studies for B-CELL LYMPHOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat brain lymphoma: drug combo enters human trials
Disease control Recruiting nowThis study tests a new drug, selinexor, added to standard chemotherapy for people with a type of lymphoma (B-cell non-Hodgkin lymphoma) that has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to find the best dose and see if the co…
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated May 17, 2026 08:05 UTC
-
Supercharged immune cells take on tough blood cancers
Disease control Recruiting nowThis early-phase trial tests a personalized therapy where a patient's own immune cells are genetically modified to recognize and attack cancer cells. It is for children and adults with certain blood cancers (like leukemia or lymphoma) that have not responded to standard treatment…
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: Nelson Hamerschlak • Aim: Disease control
Last updated May 17, 2026 08:00 UTC
-
MRNA-Powered CAR-T therapy targets tough blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with B-cell lymphoma or leukemia that has come back or not responded to standard therapy. The treatment uses special particles to deliver mRNA into the body, creating immune cells that target two cancer markers (CD19 and CD20). The goal…
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New CAR T-Cell therapy aims to control Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests a new CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to other treatments. About 30 participants will receive specially engineered immune cells targeting CD19 and/or CD22 proteins on their cancer cells. The goal is to find t…
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated May 06, 2026 16:13 UTC